Objective: Children with congenital diaphragmatic hernia (CDH) are at risk for pulmonary morbidity. Data on longitudinal evaluation of lung function in CDH are scarce. We hypothesized that CDH patients would have impaired lung function that worsens over time. We evaluated lung function and its determinants at ages 8 and 12 years.
| INTRODUCTION
Congenital diaphragmatic hernia (CDH) combines a developmental defect of the diaphragm with pulmonary hypoplasia, abnormal pulmonary vascular development, increased vasoreactivity, 1 and increased susceptibility for chronic lung disease. 2 Advances in surgical and neonatal management, and the implementation of a standardized European CDH neonatal treatment protocol since November 2007 3 (referred to as "postnatal treatment protocol") (Table S1), have significantly contributed to improved survival, with reported rates from 68% to 90%. 2, 4 The increase in survival may lead to an increase in morbidity for the survivors.
Pulmonary morbidity in CDH patients is common. 5, 6 Lung hypoplasia with persistent airflow obstruction, 7, 8 iatrogenic lung damage due to mechanical ventilation, and microstructural changes in the lung 9 are factors that may contribute to long-term pulmonary morbidity. While normal lung tissue continues to develop alveoli into adolescence, 10, 11 it is unknown if and when catch-up growth of the abnormal lungs of CDH patients will occur. 12 Besides, several studies have shown that these patients' lung development is affected by inhibited pulmonary vascular growth. 13, 14 Besides these structural pulmonary abnormalities, CDH patients suffer from gastrointestinal and respiratory problems. Gastroesophageal reflux and recurrent episodes of lower respiratory tract infections often occur not only in the first years after birth, but also later in life. [15] [16] [17] All these together may lead to decreased lung function at school age.
A previous study from our group found hyperinflation of the lungs with larger functional residual capacity and decreased expiratory flows in CDH patients' first year of life, especially among those treated with extracorporeal membrane oxygenation (ECMO). 18 While a few studies found normal pulmonary function later on, 19 other studies showed airflow obstruction, high prevalence of increased airway responsiveness and decreased diffusion capacity in CDH patients. 6, 8, 20, 21 However, many of these studies often have a cross-sectional design and evaluated lung anomalies. These children and their parents are followed by a multidisciplinary team, and eight standardized assessments are performed from the ages of 6 months to 17 years as published by our research group. 22, 23 We analyzed data of children who had been clinically stable for at least 3 weeks before the assessment of the follow-up program at ages 8 and 12 years and who performed reproducible lung function tests.
We excluded data from patients diagnosed with CDH after 7 days of age, those with paraesophageal diaphragmatic defects, those with a diaphragmatic eventration, and those with an unreliable lung function test. Until November 2007, ECMO treatment was applied in cases of reversible severe respiratory failure by using the entry criteria as reported by Stolar et al. 24 After November 2007, children were treated according to the standardized CDH EURO Consortium consensus treatment protocol which included ECMO criteria 3 (Table S1 ). These criteria were no different from earlier criteria. All data were collected during routine care and subjects were not submitted to any handling and no rules of human behavior were imposed. Therefore, institutional review board approval was waived (MEC-2016-111) . Parents of all children were routinely informed about the study and provided permission to use the deidentified data for research purposes.
| Measurements

| Baseline data
The following baseline data were recorded: sex, age, gestational age, birth weight, ethnicity, side of hernia, type of repair, duration of mechanical ventilation, ventilation-free days in the first 28 days of life, nitric oxide (NO) treatment, type of initial mechanical ventilation, duration of intensive care unit stay, duration of initial hospital stay, presence of chronic lung disease (CLD), 25 congenital cardiac anomalies, treatment with phosphodiesterase type 5 inhibitor (PDE5 treatment), β-2-mimetica, prophylactic inhaled corticosteroid, atopy, number of respiratory tract infections in the previous year treated with antibiotics prescribed by a family physician, local pediatrician or pediatric pulmonologist, treatment with prophylactic antibiotics, bronchodilators, symptoms of gastroesophageal reflux (heartburn, chest pain, regurgitation, nocturnal cough, dysphagia, and dysphonia), Nissen fundoplication, tube feeding, and dietetics.
| Lung function measurement
Airway patency was assessed with an electronic spirometer (Masterscreen PFT; Carefusion; San Diego, CA) before and after inhalation of 400 μg salbutamol. 26 Children using inhalation medication had been instructed to stop short-acting β 2 -agonists 8 hours before and long-acting β 2 -agonists 24 hours before assessment.
Forced expiratory volume in 1 second (FEV 1 ), forced vital capacity (FVC), FEV 1 /FVC and forced expiratory flows between 25% and 75% of vital capacity (FEF ) were expressed as absolute values, and as SDS based on sex-, age-, and length-related reference values. 27 Reversible airway obstruction was defined as an increase of FEV 1 > 11% after bronchodilatation (BD). 28 Total lung capacity (TLC pleth ), RV/TLC pleth ratio, and functional residual capacity (FRC pleth ) were determined by whole body plethysmography (Masterscreen Body Plethysmography; Carefusion) and expressed as absolute values and percentile scores. Diffusion capacity for carbon monoxide (DL CO ) and diffusion capacity corrected for alveolar volume (K CO ) were measured using a multigas analyzer (Masterscreen The fraction of exhaled NO (FeNO) was measured online using the NIOX analyzer (Aerocrine, Solna, Sweden) according to previously described guidelines and compared against the American Thoracic Society cutoff point. 30, 31 Equipment and procedures fulfilled European Respiratory Society criteria. 26 
| Statistical analysis
Differences in baseline data between "participants in the follow-up program" and "nonparticipants in the follow-up program" and the children "treated with neonatal ECMO" and "not treated with neonatal ECMO" were evaluated using the Mann-Whitney U tests for continuous variables and χ 2 tests for categorical variables. To Tables 1 and 2. Compared to those without ECMO treatment, children who received ECMO treatment were ventilated longer, had a higher incidence of CLD, had a longer hospital stay, needed more often patch repair, were more frequently treated with PDE5 and an atopic history was reported more frequently at 8 years.
Patient characteristics are presented in
| Lung function
SDS FEV 1 , SDS FEV 1 /FVC, and SDS FEF , before and after bronchodilation were significantly below normal at the ages of 8 and 12 years (Table 3; Although spirometry results differed significantly between ECMO and non-ECMO patients (Table 2 )-with lower spirometry results in ECMO-treated patients-ECMO had no significant effect on the deterioration of spirometry parameters (FEV 1 and FEF ).
These two groups showed a similar trend in deterioration ( Figure 2 ).
Static lung volumes, except for RV pleth and RV/TLC pleth ratio, were within normal ranges at ages 8 and 12 years (Table 3 ). Diffusion capacity, either corrected or uncorrected for alveolar volume, was significantly below normal in both groups and ages (both P ≤ .001; Table 3 ) and had not changed significantly over time ( Table 4 ). had FeNO less than 20 ppb (Table S1 ).
| Associations between lung function parameters and baseline data
Duration of initial hospital stay and ventilation-free days were excluded as independent variables from the linear mixed model because the VIFs were more than 3.0. VIFs of the other covariates F I G U R E 1 Study inclusion flowchart: a chromosome aberration (n = 1), Cohen syndrome (n = 1), Loeys-Dietz syndrome (n = 1), Simpson-Golabi-Behmel syndrome (n = 2), Wolf-Hirschhorn syndrome (n = 1), autism (n = 1), polymyalgia rheumatica (n = 2); b no lung function test performed due to a tracheacanule (n = 1), organizational reasons (n = 1); c unreliable lung function test due to insufficient technique (n = 3). BD, bronchodilatation; CDH, congenital hernia diaphragmatic; ECMO, extracorporeal membrane oxygenation; NO, nitric oxide were all less than 2.1 after removing these two independent variables.
The independent variables type of repair, type of initial ventilation and NO treatment were removed from the linear mixed model, because of P values above the cutoff of .20. Table S2 ). The FEV 1 after BD of children not treated with the postnatal treatment protocol was significantly higher than that of children treated with this protocol (0.767 [0.104 to 1.430], P = .024) (Tables S2,3 ). No other significant association was found between FEV 1 and baseline data (Table S2) . Besides, no significant interaction effects were found between timepoint of assessment and log duration of ventilation or timepoint of assessment and ECMO treatment for FEV 1 (data not shown) . Table S2 ). FEF ; open ductus botalli + atrium septum defect with surgery (n = 3); and dysplastic pulmonic valve and tricuspidalis insufficiency (n = 1). significant associations were found between FEF 25-75 and baseline data (Table S2) . Besides, no significant interaction effects were found between timepoint of assessment and log duration of ventilation or timepoint of assessment and ECMO treatment for FEF (data not shown) .
No significant associations were found between K CO and baseline data (Table S2 ).
| DISCUSSION
This longitudinal follow-up study in school-aged children born with CDH revealed deterioration of severity of airflow obstruction from 8 to 12 years, though reduced diffusion capacity corrected for alveolar volume remained stable. These findings were irrespective of ECMO treatment. The static lung volumes were within normal ranges and did not change from 8 to 12 years. Longer duration of mechanical ventilation was associated with significantly more airflow obstruction.
Most studies that have evaluated pulmonary morbidity in schoolaged children with CDH were cross-sectional and revealed airflow obstruction. 6, 8, 20, 21, 33 The study populations of Haliburton et al 21 To our knowledge, only our group has previously reported on longitudinal lung function in children and young adults who survived CDH. 6, 7 In a study of ECMO-treated patients with small numbers of CDH patients, lung function had deteriorated over time at school age. 7 In a cohort born before ECMO was introduced in the Netherlands (1991), mild airflow obstruction had deteriorated from childhood to young adulthood. 6 Microstructural pulmonary changes not only in the ipsilateral lung but also in the contralateral lung were found in nonsmoking young adults in this cohort. 9 Taking into account the very short duration of mechanical ventilation in this older group 6 We assume that ECMO-treated CDH patients have more severe lung hypoplasia, pulmonary hypertension and vascular maldevelopment than non-ECMO-treated CDH patients. Therefore, they may need longer mechanical ventilation, which is associated with risk of CLD. This may be reflected by more severe airflow obstruction at school age.
The ECMO-treated CDH patients in this study indeed had longer duration of mechanical ventilation and more often CLD. They also had significant lower spirometry parameters than non-ECMO-treated CDH patients. However, the change of airflow obstruction over time was not affected by ECMO treatment.
This suggests that CLD could be responsible for the lower spirometry parameters at school age, but not for the deterioration of these parameters. Therefore, we recommend that future research should focus on long-term longitudinal assessment of pulmonary morbidity and imaging of lung morphology into adulthood.
Interestingly the airflow obstruction in the children treated after introduction of the postnatal treatment protocol was more severe than that in the children born earlier. This result supports the aforementioned assumption that with the decreased mortality from Data are presented as estimated marginal mean (95% confidence intervals) SDS lung function parameters. Abbreviations: BD, bronchodilation; CDH, congenital diaphragmatic hernia; DL co , transfer factor for carbon monoxide; ECMO, extracorporeal membrane oxygenation; FVC, forced vital capacity; FEV 1 , forced expiratory volume in 1 s; FEF , forced expiratory flows between 25% and 75% of vital capacity, FRC pleth , functional residual capacity; K CO , diffusion capacity corrected for alveolar volume; RV pleth , plethysmographic derived residual volume; SDS, standard deviation score; TLC pleth , plethysmographic derived total lung capacity. Abbreviations: BD, bronchodilation; CDH, congenital diaphragmatic hernia; CI, confidence interval; DL co , transfer factor for carbon monoxide; ECMO, extracorporeal membrane oxygenation; K CO, diffusion capacity corrected for alveolar volume ; FEV 1 , forced expiratory volume in 1 s, FEF , forced expiratory flows between 25% and 75% of vital capacity; FVC, forced vital capacity; FRC pleth , functional residual capacity, RV pleth , plethysmographic derived residual volume; SDS, standard deviation score, TLC pleth , plethysmographic derived total lung capacity. Significant change of estimated mean differences (based on estimated marginal means) from 8 to 12 y: *P ≤ .001; **P ≤ .01 F I G U R E 2 FEV 1 and FEF before bronchodilation from 8 to 12 years. Data shown are linear mixed models estimates of mean values with 95% confidence intervals. Circles: CDH with ECMO, lozenge: CDH without ECMO. CDH, congenital diaphragmatic hernia; ECMO, extracorporeal membrane oxygenation; FEV 1 , forced expiratory volume in 1 second;FEF , forced expiratory flows between 25% and 75% of vital capacity; SDS, standard deviation score significant differences in baseline data reflecting severity of illness between the participants and nonparticipants of our follow-up program. Selection bias is therefore unlikely.
Several limitations need to be addressed, however. First, data of only a relatively small number of children assessed at 12 years of age (n = 37) were included, although mixed models account for data missing at random. Secondly, although we had a large number of reliable lung function tests, some lung function assessment data were missing 
